81_FR_69735 81 FR 69541 - Government-Owned Inventions; Availability for Licensing

81 FR 69541 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 194 (October 6, 2016)

Page Range69541-69542
FR Document2016-24134

The invention listed below is owned by an agency of the U.S. Government and is available for licensing.

Federal Register, Volume 81 Issue 194 (Thursday, October 6, 2016) 
[Federal Register Volume 81, Number 194 (Thursday, October 6, 2016)]
[Notices]
[Pages 69541-69542]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-24134]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent application listed below may be obtained by 
communicating with the indicated licensing contact at the Technology 
Transfer and Intellectual Property Office, National Institute of 
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: The invention listed below is owned by an 
agency of the U.S. Government and is available for licensing in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing. Technology description follows.
    Use of Roseomonas species to treat eczematous (atopic dermatitis) 
skin disease Description of Technology:
    Atopic dermatitis, also known as eczema, is a chronic itchy skin 
disease that affects over 20% of infants and young children in 
industrialized nations and may persist into adulthood for up to 50% of 
these cases, making it one of the most common skin diseases in the US 
and other developed countries.
    Scientists at NIAID have developed a method of treating or 
preventing atopic dermatitis via the topical application of selected 
probiotic strains of gram-negative Roseomonas mucosa bacteria. This 
approach avoids the exhausting treatment demands of standard therapies 
and has been shown to be beneficial in a preclinical mouse model of 
atopic dermatitis.
    Potential Commercial Applications:

 Treatment of eczema

    Competitive Advantages:

 May be formulated as a cream or ointment

[[Page 69542]]

 Corticosteroid-free
 Animal data available

    Development Stage:

 In vivo data available (animal)

    Inventors: Ian A. Myles, Sandip Kumar Datta, all of NIAID.
    Publications: Myles IA, et al. Transplantation of human skin 
microbiota in models of atopic dermatitis. JCI Insight, 2016, Jul 7; 
1(10). [PMID 27478874].
    Intellectual Property: HHS Reference No. E-099-2016/0--US Patent 
Application No. 62/324,762 filed April 19, Year 2016.
    Licensing Contact: Dr. David Yang, 240-627-3413; 
[email protected]. Collaborative Research Opportunity: The National 
Institute of Allergy and Infectious Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize the use of 
Roseomonas species to treat eczematous (atopic dermatitis) skin 
disease. For collaboration opportunities, please contact Dr. David 
Yang, 240-627-3413; [email protected].

    Dated: Septenber 30, 2016.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2016-24134 Filed 10-5-16; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 194 / Thursday, October 6, 2016 / Notices 69541 Name of Committee: Center for Scientific Rockville, MD 20892, (240) 669–5060, DEPARTMENT OF HEALTH AND Review Special Emphasis Panel; Drug james.snyder@nih.gov. HUMAN SERVICES Discovery and Mechanisms of Antimicrobial (Catalogue of Federal Domestic Assistance Resistance. Program Nos. 93.855, Allergy, Immunology, National Institutes of Health Date: November 3, 2016. and Transplantation Research; 93.856, Time: 1:00 p.m. to 3:00 p.m. Microbiology and Infectious Diseases Government-Owned Inventions; Agenda: To review and evaluate grant Research, National Institutes of Health, HHS) Availability for Licensing applications. Place: Hilton McLean Tysons Corner, 7920 Dated: September 30, 2016. AGENCY: National Institutes of Health, Jones Branch Drive, McLean, VA 22102. Natasha M. Copeland, HHS. Contact Person: John C. Pugh, Ph.D., Program Analyst, Office of Federal Advisory ACTION: Notice. Scientific Review Officer, Center for Committee Policy. Scientific Review, National Institutes of SUMMARY: The invention listed below is [FR Doc. 2016–24129 Filed 10–5–16; 8:45 am] Health, 6701 Rockledge Drive, Room 3114, owned by an agency of the U.S. MSC 7808, Bethesda, MD 20892, (301) 435– BILLING CODE 4140–01–P 2398, pughjohn@csr.nih.gov. Government and is available for licensing. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; DEPARTMENT OF HEALTH AND FOR FURTHER INFORMATION CONTACT: 93.333, Clinical Research, 93.306, 93.333, HUMAN SERVICES Licensing information and copies of the 93.337, 93.393–93.396, 93.837–93.844, U.S. patent application listed below 93.846–93.878, 93.892, 93.893, National National Institutes of Health may be obtained by communicating Institutes of Health, HHS) with the indicated licensing contact at National Institute of Allergy and the Technology Transfer and Dated: September 30, 2016. Infectious Diseases: Notice of Closed Intellectual Property Office, National Natasha M. Copeland, Meeting Program Analyst, Office of Federal Advisory Institute of Allergy and Infectious Committee Policy. Diseases, 5601 Fishers Lane, Rockville, Pursuant to section 10(d) of the [FR Doc. 2016–24126 Filed 10–5–16; 8:45 am] MD 20852; tel. 301–496–2644. A signed Federal Advisory Committee Act, as Confidential Disclosure Agreement will BILLING CODE 4140–01–P amended (5 U.S.C. App.), notice is be required to receive copies of hereby given of the following meeting. unpublished patent applications. DEPARTMENT OF HEALTH AND The meeting will be closed to the SUPPLEMENTARY INFORMATION: The HUMAN SERVICES public in accordance with the invention listed below is owned by an provisions set forth in sections agency of the U.S. Government and is National Institutes of Health 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., available for licensing in the U.S. in as amended. The grant applications and accordance with 35 U.S.C. 209 and 37 National Institute of Allergy and the discussions could disclose CFR part 404 to achieve expeditious Infectious Diseases: Notice of Closed confidential trade secrets or commercial commercialization of results of Meeting property such as patentable material, federally-funded research and and personal information concerning development. Foreign patent Pursuant to section 10(d) of the individuals associated with the grant applications are filed on selected Federal Advisory Committee Act, as applications, the disclosure of which inventions to extend market coverage amended (5 U.S.C. App.), notice is would constitute a clearly unwarranted for companies and may also be available hereby given of the following meeting. invasion of personal privacy. for licensing. Technology description The meeting will be closed to the public in accordance with the Name of Committee: National Institute of follows. provisions set forth in sections Allergy and Infectious Diseases Special Use of Roseomonas species to treat 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Emphasis Panel Consortium for Food Allergy eczematous (atopic dermatitis) skin Research: Clinical Research Units (UM1). disease Description of Technology: as amended. The grant applications and Date: November 16–18, 2016. Atopic dermatitis, also known as the discussions could disclose Time: 7:30 p.m. to 6:00 p.m. confidential trade secrets or commercial eczema, is a chronic itchy skin disease Agenda: To review and evaluate grant that affects over 20% of infants and property such as patentable material, applications. and personal information concerning young children in industrialized nations Place: The William F. Bolger Center, 9600 individuals associated with the grant Newbridge Drive, Potomac, MD 20854. and may persist into adulthood for up applications, the disclosure of which Contact Person: Louis A. Rosenthal, Ph.D., to 50% of these cases, making it one of would constitute a clearly unwarranted Scientific Review Officer Scientific Review the most common skin diseases in the invasion of personal privacy. Program, Division of Extramural Activities, US and other developed countries. Rm 3G42B National Institutes of Health/ Scientists at NIAID have developed a Name of Committee: National Institute of NIAID, 5601 Fishers Lane, MSC–79823 method of treating or preventing atopic Allergy and Infectious Diseases Special Bethesda, MD 20892–9823, (240) 669–5070, dermatitis via the topical application of Emphasis Panel; Lasker Clinical Research rosenthalla@niaid.nih.gov. selected probiotic strains of gram- Scholars Program (Si2/R00). Date: November 1, 2016. (Catalogue of Federal Domestic Assistance negative Roseomonas mucosa bacteria. Time: 2:00 p.m. to 5:00 p.m. Program Nos. 93.855, Allergy, Immunology, This approach avoids the exhausting Agenda: To review and evaluate grant and Transplantation Research; 93.856, treatment demands of standard applications. Microbiology and Infectious Diseases therapies and has been shown to be sradovich on DSK3GMQ082PROD with NOTICES Place: National Institutes of Health, 5601 Research, National Institutes of Health, HHS) beneficial in a preclinical mouse model Fishers Lane, Rockville, MD 20892, Dated: September 30, 2016. of atopic dermatitis. (Telephone Conference Call). Natasha M. Copeland, Potential Commercial Applications: Contact Person: James T. Snyder, Ph.D., • Treatment of eczema Program Analyst, Office of Federal Advisory Scientific Review Officer, Scientific Review Committee Policy. Competitive Advantages: Program, Division of Extramural Activities/ Room 3G31B National Institutes of Health, [FR Doc. 2016–24130 Filed 10–5–16; 8:45 am] • May be formulated as a cream or NIAID, 5601 Fishers Lane MSC 9823, BILLING CODE 4140–01–P ointment VerDate Sep<11>2014 18:46 Oct 05, 2016 Jkt 241001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1

69542 Federal Register / Vol. 81, No. 194 / Thursday, October 6, 2016 / Notices • Corticosteroid-free Agenda: To review and evaluate grant Name of Committee: Board of Scientific • Animal data available applications. Counselors for Basic Sciences, National Place: Hilton Garden Inn, 7301 Waverly Cancer Institute. Development Stage: Street, Bethesda, MD 20817. Date: November 14, 2016. • In vivo data available (animal) Contact Person: Ramesh Vemuri, Ph.D., Time: 6:00 p.m. to 9:00 p.m. Inventors: Ian A. Myles, Sandip Chief, Scientific Review Branch, National Agenda: To review and evaluate personal Kumar Datta, all of NIAID. Institute on Aging, National Institutes of qualifications and performance, and Publications: Myles IA, et al. Health, 7201 Wisconsin Avenue, Suite competence of individual investigators. Transplantation of human skin 2W200, Bethesda, MD 20892, 301–402–7700, Place: Hyatt Regency, 1 Bethesda Metro rv23r@nih.gov. microbiota in models of atopic Center, Bethesda, MD 20814. dermatitis. JCI Insight, 2016, Jul 7; 1(10). (Catalogue of Federal Domestic Assistance Contact Person: Mehrdad Tondravi, Ph.D., [PMID 27478874]. Program Nos. 93.866, Aging Research, Chief, Institute Review Office, National National Institutes of Health, HHS) Intellectual Property: HHS Reference Cancer Institute, National Institutes of No. E–099–2016/0—US Patent Dated: September 30, 2016. Health, 9609 Medical Center Drive, Room Application No. 62/324,762 filed April 3W302, Rockville, MD 20850, 240–276–5660, Melanie J. Gray, 19, Year 2016. tondravim@mail.nih.gov. Program Analyst, Office of Federal Advisory Licensing Contact: Dr. David Yang, Committee Policy. Name of Committee: Board of Scientific 240–627–3413; polung.yang@nih.gov. Counselors for Clinical Sciences and [FR Doc. 2016–24128 Filed 10–5–16; 8:45 am] Collaborative Research Opportunity: Epidemiology, National Cancer Institute. BILLING CODE 4140–01–P The National Institute of Allergy and Date: November 14, 2016. Infectious Diseases is seeking statements Time: 6:00 p.m. to 9:00 p.m. of capability or interest from parties Agenda: To review and evaluate personal DEPARTMENT OF HEALTH AND qualifications and performance, and interested in collaborative research to HUMAN SERVICES competence of individual investigators. further develop, evaluate or commercialize the use of Roseomonas Place: Hyatt Regency, 1 Bethesda Metro National Institutes of Health species to treat eczematous (atopic Center, Bethesda, MD 20814. dermatitis) skin disease. For National Cancer Institute; Notice of Contact Person: Brian E. Wojcik, Ph.D., collaboration opportunities, please Closed Meetings Executive Secretary, Institute Review Office, contact Dr. David Yang, 240–627–3413; Office of the Director, National Cancer polung.yang@nih.gov. Pursuant to section 10(d) of the Institute, National Institutes of Health, 9609 Federal Advisory Committee Act, as Medical Center Drive, Room 3W414, Dated: Septenber 30, 2016. amended (5 U.S.C. App.), notice is Rockville, MD 20850, 240–276–5660, Suzanne Frisbie, wojcikb@mail.nih.gov. Deputy Director, Technology Transfer and hereby given of meetings of the Board of Scientific Counselors for Basic Sciences, Name of Committee: Board of Scientific Intellectual Property Office, National Institute National Cancer Institute and the Board Counselors for Clinical Sciences and of Allergy and Infectious Diseases. of Scientific Counselors for Clinical Epidemiology, National Cancer Institute. [FR Doc. 2016–24134 Filed 10–5–16; 8:45 am] Sciences and Epidemiology, National Date: November 15, 2016. BILLING CODE 4140–01–P Cancer Institute. Time: 8:30 a.m. to 2:45 p.m. Agenda: To review and evaluate personal The meetings will be closed to the qualifications and performance, and DEPARTMENT OF HEALTH AND public as indicated below in accordance competence of individual investigators. HUMAN SERVICES with the provisions set forth in section Place: National Institutes of Health, 31 552b(c)(6), Title 5 U.S.C., as amended Center Drive, Building 31, C-Wing, 6th Floor, National Institutes of Health for the review, discussion, and Conference Room 6, Bethesda, MD 20892. evaluation of individual intramural Contact Person: Brian E. Wojcik, Ph.D., National Institute on Aging: Notice of programs and projects conducted by the Executive Secretary, Institute Review Office, Closed Meeting National Cancer Institute, including Office of the Director, National Cancer Pursuant to section 10(d) of the consideration of personnel Institute, National Institutes of Health, 9609 Federal Advisory Committee Act, as qualifications and performance, and the Medical Center Drive, Room 3W414, amended (5 U.S.C. App.), notice is competence of individual investigators, Rockville, MD 20850, 240–276–5665, hereby given of the following meeting. the disclosure of which would wojcikb@mail.nih.gov. The meeting will be closed to the constitute a clearly unwarranted (Catalogue of Federal Domestic Assistance public in accordance with the invasion of personal privacy. Program Nos. 93.392, Cancer Construction; provisions set forth in sections Name of Committee: Board of Scientific 93.393, Cancer Cause and Prevention 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Counselors for Basic Sciences, National Research; 93.394, Cancer Detection and as amended. The grant applications and Cancer Institute. Diagnosis Research; 93.395, Cancer the discussions could disclose Date: November 14, 2016. Treatment Research; 93.396, Cancer Biology confidential trade secrets or commercial Time: 9:00 a.m. to 2:30 p.m. Research; 93.397, Cancer Centers Support; property such as patentable material, Agenda: To review and evaluate personal 93.398, Cancer Research Manpower; 93.399, and personal information concerning qualifications and performance, and Cancer Control, National Institutes of Health, individuals associated with the grant competence of individual investigators. HHS) Place: National Institutes of Health, 31 sradovich on DSK3GMQ082PROD with NOTICES applications, the disclosure of which Dated: September 30, 2016. Center Drive, Building 31, C-Wing, 6th Floor, would constitute a clearly unwarranted Conference Room 6, Bethesda, MD 20892. Melanie J. Gray, invasion of personal privacy. Contact Person: Mehrdad Tondravi, Ph.D., Program Analyst, Office of Federal Advisory Name of Committee: National Institute on Chief, Institute Review Office, Office of the Committee Policy. Aging Special Emphasis Panel Second Stage Director, National Cancer Institute, National P01 Review. Institutes of Health, 9609 Medical Center [FR Doc. 2016–24127 Filed 10–5–16; 8:45 am] Date: November 21, 2016. Drive, Room 3W302, Rockville, MD 20850, BILLING CODE 4140–01–P Time: 8:00 a.m. to 5:00 p.m. 240–276–5660, tondravim@mail.nih.gov. VerDate Sep<11>2014 18:46 Oct 05, 2016 Jkt 241001 PO 00000 Frm 00034 Fmt 4703 Sfmt 9990 E:\FR\FM\06OCN1.SGM 06OCN1


Document Created: 2016-10-06 02:38:14
Document Modified: 2016-10-06 02:38:14
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation81 FR 69541 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR